J.P. Marvel Investment Advisors LLC Reduces Stock Holdings in Danaher Co. (NYSE:DHR)

by · The Cerbat Gem

J.P. Marvel Investment Advisors LLC cut its holdings in Danaher Co. (NYSE:DHR – Free Report) by 0.3% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 34,180 shares of the conglomerate’s stock after selling 105 shares during the quarter. Danaher makes up about 1.6% of J.P. Marvel Investment Advisors LLC’s investment portfolio, making the stock its 19th largest position. J.P. Marvel Investment Advisors LLC’s holdings in Danaher were worth $9,503,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in shares of Danaher by 7.4% in the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after purchasing an additional 4,163,657 shares during the last quarter. Swedbank AB acquired a new stake in Danaher during the 1st quarter valued at $676,545,000. TD Asset Management Inc increased its position in Danaher by 99.0% during the second quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock worth $339,473,000 after buying an additional 675,952 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Danaher by 22.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock worth $761,475,000 after acquiring an additional 563,546 shares during the last quarter. Finally, International Assets Investment Management LLC lifted its position in shares of Danaher by 40,196.5% in the third quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after acquiring an additional 428,897 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 10.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on DHR shares. Royal Bank of Canada cut their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Bank of America boosted their price objective on shares of Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Raymond James decreased their target price on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Stephens reiterated an “overweight” rating and issued a $315.00 price target on shares of Danaher in a report on Wednesday, October 23rd. Finally, Wolfe Research upgraded Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a report on Thursday, October 31st. Five research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $287.16.

Get Our Latest Research Report on Danaher

Danaher Trading Down 0.7 %

Shares of DHR stock opened at $246.10 on Friday. Danaher Co. has a fifty-two week low of $192.35 and a fifty-two week high of $281.70. The firm’s 50 day moving average price is $265.79 and its two-hundred day moving average price is $260.75. The stock has a market cap of $177.75 billion, a price-to-earnings ratio of 46.97, a price-to-earnings-growth ratio of 4.54 and a beta of 0.85. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR – Get Free Report) last announced its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the prior year, the company earned $2.02 EPS. The firm’s revenue was up 3.1% on a year-over-year basis. On average, analysts anticipate that Danaher Co. will post 7.51 EPS for the current year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were issued a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s payout ratio is currently 20.61%.

Danaher Company Profile

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Stories

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).